Table 5 Overall Survival after Diagnosis and Third-line Treatment

Treatment

Rechallenge

123

48.73 (42.12–55.33)

.001

11.99 (9.49–14.49)

< .001

Regorafenib

259

37.95 (34.65–41.24)

8.08 (6.88–9.29)

Age, years

< 60

218

44.49 (39.72–49.25)

.101

9.43 (7.86–10.99)

.557

≥ 60

163

40.27 (34.83–45.67)

10.05 (8.27–11.83)

Sex

Female

157

44.91 (43.17–46.64)

.011

11.30 (9.09–13.51)

< .001

Male

215

39.33 (36.03–42.26)

8.08 (6.20–9.96)

ECOG PS

0/1

260

42.78 (37.96–47.59)

.199

10.58 (8.63–12.52)

.138

2

48

37.65 (24.04–51.26)

6.64 (4.89–8.38)

Tumor side

Right

69

32.33 (23.88–40.78)

.024

7.62 (5.67–9.58)

.074

Left

312

44.65 (41.61–47.69)

10.05 (8.66–11.45)

Metastases status^a

Synchronous

229

34.07 (29.72–38.43)

< 0.001

9.43 (8.12–10.74)

.164

Metachronous

153

57.66 (49.38–65.94)

9.63 (7.17–12.08)

Response to first 2 lines

Disease control in both lines

248

47.08 (43.63–50.53)

< .001

10.74 (9.59–11.89)

.001

Disease control in 1 line

119

31.80 (24.37–39.24)

7.56 (5.64–9.47)

Resistant to both lines

15

14.92 (11.59–18.23)

3.94 (2.82–5.06)